Northwest Biotherapeutics makes changes to management team
Linda Powers becomes chief executive
Linda Powers, who has been chairman since May 2007, has become chief executive, while Dr Anthony Maida, a senior executive in the field of cancer immune therapies, is joining the company as chief operating officer on 20 June.
Dr Alton Boynton, the scientific founder of NWBT and chief executive since May 2007, is returning to the position of chief scientific officer.
Les Goldman, a former partner at US law firm Skadden, Arps, specialising in advanced technology commercialisation, has been appointed as senior vice president, business development. Dr Marnix Bosch will continue in his role as chief technology officer.
You may also like
Cleaning
Guardtech partner with Intense Pulsed Light innovators Biopulz to offer game-changing new cleanroom decontamination solution
New partnership will give Guardtech clients access to Biopulz’s mobile Eloane tower and integrated E-z̈o IPL decontamination system as part of their cleanroom installation projects
Analysis
Inspection readiness should be part of normal operations
For routine surveillance inspections, readiness cannot depend on receiving advance notice. Inspection readiness should be embedded in everyday operations, while recognising that preparation may need to become more intensive ahead of a known regulatory milestone
Pharmaceutical
T-Cypher Bio relocates to new Oxford facility to advance immune engager pipeline
The biotech firm has moved to a new facility at Abingdon Science Park, expanding its laboratory and tissue culture capabilities to support IND-enabling studies and the development of next-generation T-cell receptor-based therapeutics
Research & Development
TUM develops GNExT platform to identify potential Alzheimer’s drug candidates
The Technical University of Munich has developed a web-based tool that connects genome-wide association study data with biological networks, helping researchers identify disease mechanisms and potential drug repurposing opportunities